High-performance liquid chromatographic determination of alizapride, a new antiemetic compound, and its application to a dose-dependent pharmacokinetic study.
An assay was developed to measure alizapride (a new antiemetic compound) in biological specimens. The method involved reversed-phase high-performance liquid chromatography and fluorescence detection. The detection limit was 5 ng/ml in plasma or urine samples. The value of the assay was demonstrated with a dose-dependent pharmacokinetic study. It showed a two-phase decrease in plasma concentrations, after intravenous injection, with half-lives of 7.5-min and 2.5-hr, respectively. From plasma and urine results, pharmacokinetic parameters remained constant in the dose range of 50-200 mg.
D000284:Administration, Oral; D000932:Antiemetics / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D011759:Pyrrolidines / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism
D000932:Antiemetics; D011759:Pyrrolidines; C033968:alizapride